Health Care & Life Sciences » Medical Equipment & Supplies | Sysmex Corp.

Sysmex Corp. | Income Statement

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Sales/Revenue
184,538
221,376
252,622
249,899
281,935
293,506
Cost of Goods Sold (COGS) incl. D&A
71,810
98,993
101,932
108,122
122,986
131,899
Gross Income
112,728
122,383
150,690
141,777
158,949
161,607
SG&A Expense
78,005
77,972
89,980
90,955
99,002
100,808
EBIT
34,723
44,411
-
50,822
59,947
60,799
Unusual Expense
138
113
5
314
1,406
319
Non Operating Income/Expense
620
1,324
2,611
1,547
553
890
Interest Expense
41
44
44
151
169
70
Pretax Income
33,451
45,727
58,274
49,623
58,117
57,955
Income Tax
12,878
19,089
18,530
8,493
19,040
16,789
Equity in Affiliates
-
-
465
677
-
-
Consolidated Net Income
20,573
26,638
39,278
40,453
39,076
41,166
Net Income
20,573
26,638
39,278
40,635
39,221
41,224
Net Income After Extraordinaries
20,573
26,638
39,278
40,635
39,221
41,224
Net Income Available to Common
20,573
26,638
39,278
40,636
39,222
41,224
EPS (Basic)
99.47
128.49
189.08
195.31
188.29
197.60
Basic Shares Outstanding
207
207
208
208
208
209
EPS (Diluted)
99.16
128.02
188.30
194.74
187.84
197.29
Diluted Shares Outstanding
207
208
209
209
209
209
EBITDA
46,118
57,364
72,820
63,203
74,590
76,641
Non-Operating Interest Income
170
232
252
188
252
230
Minority Interest Expense
-
-
-
182
145
58
Equity in Affiliates (Pretax)
30
83
-
-
1,059
1,793

About Sysmex

View Profile
Address
1-5-1 Wakinohama-Kaigandori
Kobe Hyogo 651
Japan
Employees -
Website http://www.sysmex.co.jp
Updated 07/08/2019
Sysmex Corp. engages in the development, manufacture, import, export, and sale of clinical laboratory instruments, reagents, and software used in in-vitro diagnostics. It also provides clinical laboratory testing of blood, urine, and other specimens. Its products include instruments and reagents diagnostics for hemostasis, immunochemistry, clinical chemistry, urinalysis, and point-of-care (POC) testing.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.